EyePoint Pharmaceuticals Inc

詳細情報 EyePoint Pharmaceuticals Inc 企業名

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

企業情報

企業コードEYPT

会社名EyePoint Pharmaceuticals Inc

上場日Jan 27, 2005

最高経営責任者「CEO」Dr. Jay S. Duker, M.D.

従業員数165

証券種類Ordinary Share

決算期末Jan 27

本社所在地480 Pleasant Street, Suite C400

都市WATERTOWN

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号02472

電話番号16179265000

ウェブサイトhttps://eyepointpharma.com/

企業コードEYPT

上場日Jan 27, 2005

最高経営責任者「CEO」Dr. Jay S. Duker, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

41.78K

--

Dr. Reginald J Sanders, M.D.

Non-Executive Independent Director

--

Mr. Fred Hassan

Non-Executive Independent Director

--

Mr. Stern

Investor Relations

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

YUTIQ

3.10M

7.16%

地域別USD

会社名

収益

比率

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

事業別

地域別

事業別USD

会社名

収益

比率

YUTIQ

3.10M

7.16%

株主

更新時刻: Fri, Jul 25

株主統計

種類

株主統計

比率

Cormorant Asset Management, LP

12.10%

Suvretta Capital Management, LLC

9.89%

Adage Capital Management, L.P.

9.01%

BlackRock Institutional Trust Company, N.A.

7.19%

Franklin Advisers, Inc.

5.99%

Other

55.83%

株主統計

比率

Cormorant Asset Management, LP

12.10%

Suvretta Capital Management, LLC

9.89%

Adage Capital Management, L.P.

9.01%

BlackRock Institutional Trust Company, N.A.

7.19%

Franklin Advisers, Inc.

5.99%

Other

55.83%

種類

株主統計

比率

Hedge Fund

39.71%

Investment Advisor

28.58%

Investment Advisor/Hedge Fund

22.88%

Venture Capital

7.91%

Research Firm

5.09%

Private Equity

4.39%

Individual Investor

3.52%

Bank and Trust

1.52%

Pension Fund

0.40%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

384

78.48M

114.05%

-10.35M

2025Q1

386

76.27M

110.90%

-11.90M

2024Q4

373

75.75M

111.39%

+202.32K

2024Q3

358

60.55M

112.89%

-8.01M

2024Q2

345

60.80M

116.35%

-2.75M

2024Q1

328

57.32M

114.97%

+528.95K

2023Q4

282

52.72M

108.16%

+11.49M

2023Q3

239

37.39M

106.16%

-1.26M

2023Q2

224

35.30M

102.90%

-4.83M

2023Q1

220

33.02M

96.37%

-5.12M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Cormorant Asset Management, LP

8.32M

12.1%

--

Mar 31, 2025

Suvretta Capital Management, LLC

6.80M

9.89%

+21.00K

+0.31%

Mar 31, 2025

Adage Capital Management, L.P.

6.20M

9.01%

+450.00K

+7.83%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.95M

7.19%

+206.82K

+4.36%

Mar 31, 2025

Franklin Advisers, Inc.

4.12M

5.99%

+9.56K

+0.23%

Mar 31, 2025

The Vanguard Group, Inc.

3.82M

5.55%

+31.14K

+0.82%

Mar 31, 2025

Federated Hermes Global Investment Management Corp.

3.71M

5.39%

+2.50K

+0.07%

Mar 31, 2025

TCG Crossover Management, LLC

3.57M

5.19%

--

Mar 31, 2025

RA Capital Management, LP

3.18M

4.62%

--

Mar 31, 2025

Citadel Advisors LLC

2.29M

3.32%

-180.78K

-7.33%

Mar 31, 2025

詳細を見る

10.090USD

EyePoint Pharmaceuticals Inc

10.090

概要

企業名

金融